medical cannabis Exilby is scheduled to launch in Germany and Austria at the end of August after receiving marketing authorization from regulators. Vertanical, the developer, says Exilby is a full-spectrum extract of Cannabis sativa that combines THC, CBD and terpenes and was approved specifically for chronic lower back pain.
Regulatory and rollout plan Vertanical founder Dr. Clemens Fischer told press the company will begin sales in Germany and Austria and then expand across Europe in phases. He cited a German provision that allows doctors to prescribe Exilby to patients with any chronic pain who have exhausted other adequate treatments. “We launch at the end of August in Germany and Austria, and then we go to Europe step by step,” Fischer said.
U.S. pathway and clinical program In the United States, the FDA granted Exilby Breakthrough Therapy designation, which accelerates development and review. Vertanical plans a Phase 3, placebo-controlled trial testing Exilby for chronic back pain caused by lumbosacral radiculopathy (sciatica). The trial will recruit 810 patients at sites across the U.S.; recruitment is expected to start in the coming weeks and the study’s estimated completion date is 2028. If the Phase 3 results meet predefined endpoints, Vertanical will file a New Drug Application with the FDA. Company estimates place full FDA approval in 2028 or 2029, reflecting the time needed for trial conduct, data analysis and regulatory review.
Alternative U.S. route Federal and state actions on medical cannabis could offer a faster route to U.S. patients. The article describing Exilby’s plans notes that some state-approved medical cannabis products are being reclassified at the federal level as Schedule III substances, which would permit medical distribution. Vertanical’s leadership says it has considered selling Exilby through state-licensed dispensaries but prefers to pursue the pharmaceutical track and FDA approval.
Trial results and clinical profile Vertanical reports two completed Phase 3 studies in Europe where Exilby outperformed moderate-dose opioids — defined in the studies as 27 to 32 morphine milligram equivalents (MME) per day — for treating chronic low back pain. Patients on Exilby also logged improved sleep scores and had lower rates of constipation compared with the opioid group.
Dose and tolerability Each marketed dose of Exilby contains 2.5 mg of THC. Vertanical reports that trial participants did not experience intoxication or subjective “high” at therapeutic doses. Side-effect profiles from the Phase 3 studies showed lower opioid-linked gastrointestinal effects and sleep improvement as measurable outcomes.
Planned additional indications Vertanical has stated intentions to seek additional indications for Exilby, including osteoarthritis and peripheral neuropathy. These steps would require indication-specific trials or supportive data submitted to regulators.
What clinicians and patients should expect – Indication at launch: chronic lower back pain. – Geographic launch: Germany and Austria at the end of August, followed by staged European rollouts. – U.S. timeline: Phase 3 enrollment of 810 patients beginning soon, estimated trial completion in 2028, potential FDA approval in 2028–2029 if results are positive. – Dose: 2.5 mg THC per administered dose; formulation contains THC, CBD and terpenes from Cannabis sativa.
Context and implications The Exilby approval in Germany and Austria introduces a regulated, pharmaceutical-format cannabis extract specifically labeled for chronic lower back pain. The Phase 3 U.S. trial and Breakthrough Therapy designation reflect the company’s effort to secure full FDA approval rather than rely on state dispensary distribution. If Exilby’s U.S. Phase 3 trial reproduces the reported European results, clinicians would gain an additional, non-opioid-labeled option backed by randomized data and formal regulatory approval.
Next steps Vertanical will begin European launches as planned and start U.S. Phase 3 recruitment. Observers will watch trial enrollment rates, primary endpoint outcomes for pain reduction, and regulatory filings. Positive Phase 3 data would trigger a New Drug Application to the FDA; negative or inconclusive results would likely delay or change U.S. commercialization plans.
For patients and prescribers, the key measurable items to track are trial enrollment numbers, primary and secondary endpoint results (pain scores, sleep quality, constipation rates), and the timeline for FDA review. Vertanical’s public statements set a clear sequence: European launch, U.S. Phase 3 trial, then an FDA submission if data support it.
